During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Richard W. Joseph, MD, notes that the armamentarium of agents for the treatment of cancers such as metastatic melanoma is growing. Dr Joseph also explains the rationale for getting patients with melanoma on immunotherapy.
Dr Joseph, an assistant professor in the division of medical oncology at the Mayo Clinic in Jacksonville, Florida, discusses the difference in treatment outcomes for immunotherapies versus targeted therapies and explains that while targeted therapies and immunotherapies are both main options in metastatic melanoma, most medical oncologists prefer to treat their patients with immunotherapy.
“Immunotherapies are the only therapies that are going to cause long, durable remissions,” he says.
Unfortunately, due to a lack of data, healthcare professionals do not have much guidance on whether to begin treatment with immunotherapy or a targeted therapy, explains Dr Joseph. Currently, clinicians make treatment decisions based on disease severity. Patients with less symptomatic disease start with immunotherapy, whereas patients with bulky disease start with a targeted agent, then transition to immunotherapy.
Dr Joseph further discusses the potential of immunotherapy in the treatment of bulky disease, and expressed the hope that newer agents that work more rapidly, and the use of combination therapy, may be more effective in treating bulky disease.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More